Skip to main content
. 2020 Mar 4;32:101485. doi: 10.1016/j.redox.2020.101485

Fig. 2.

Fig. 2

BC-1901S is a proteasome-independent NRF2 stabilizer. A) Structure of BC-1901S. B) BC-1901S dose course study in NRF2 Nano-Luc cells after 16 h treatment. Data and mean ± SD of 3 independent experiments. C) Cell viability assay (MTT) with BC-1901S dose course after 16 h. Data and mean ± SD of 3 independent experiments. D, E) Chymotrypsin-like (D) and Caspase-like activity (E) (normalized) after 16 h BC-1901S treatment in Beas-2B cells. Data and mean ± SD of 3 independent experiments. F) Immunoblot analysis of total K-48 ubiquitinated proteins after 16 h BC-1901S or MG132 treatment. ns = not significant; P < 0.05, *; P < 0.01, **; P < 0.001, ***; P < 0.0001, ****; by one-way ANOVA with adjusted P-value for multiple comparisons (Dunnett's) compared to control or “0”.